Whitepaper – Overcoming Bioanalytical Challenges in Anti-Drug Antibody Detection for Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) offer groundbreaking targeted therapies in oncology and beyond, but their complexity presents unique bioanalytical challenges—especially in detecting anti-drug antibodies (ADAs) that impact safety and efficacy.

This whitepaper is your essential resource to:

• Understand the key analytical challenges in ADA detection specific to ADCs, including multidomain structures and immunogenicity impacts.
• Discover advanced assay strategies and reagent optimization methods that improve ADA detection sensitivity and specificity.
• Learn from a detailed case study highlighting real-world challenges such as pre-existing antibodies, hook effects, and signal cross-talk during clinical sample testing.
• Explore innovative mitigation techniques tailored for ADA and neutralizing antibody (NAb) assays to ensure robust, reliable clinical study data.

Why You Should Read This Whitepaper:

• Gain expert knowledge to design and validate immunogenicity assays that accurately detect ADAs in complex ADC therapies.
• Enhance your understanding of assay interference and cutting-edge solutions to overcome these obstacles.
• Access practical case insights demonstrating how effective assay strategies can drive confident clinical decision-making.
• Stay ahead in drug development by ensuring reliable immunogenicity monitoring, improving patient safety and therapeutic outcomes.

Download the whitepaper to empower your research and development program with actionable, scientifically grounded strategies for ADA detection in ADCs.